NCT03997448 2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Big Ten Cancer Research Consortium
Phase 2 Terminated
Clinical Trials
14 trialsNCT03000179 2022-04-14
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01660711 2021-11-08
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
Phase 2 Completed
NCT02987829 2021-04-23
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed
NCT01206296 2021-03-09
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
Medstar Health Research Institute
Phase 2 Terminated
NCT02487277 2020-01-02
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
University of California, San Francisco
Phase 2 Terminated
NCT00548548 2017-06-14
AVAGAST
Genentech, Inc.
Phase 3 Completed
NCT00201734 2016-09-23
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Ohio State University Comprehensive Cancer Center
Phase 1/2 Terminated
NCT01253525 2014-06-18
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
Eli Lilly and Company
Phase 1 Completed
NCT01124786 2014-04-17
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Clovis Oncology, Inc.
Phase 2 Completed
NCT00203892 2014-04-16
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma
University of Chicago
Phase 1/2 Completed
NCT00661830 2013-11-21
Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT00597506 2012-12-27
BEV/EV
Duke University
Phase 2 Completed